Sensus Healthcare (NASDAQ:SRTS) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) from a hold rating to a sell rating in a research note published on Thursday morning.

Several other equities research analysts also recently weighed in on the company. Lake Street Capital cut their price target on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Maxim Group cut their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Finally, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Sensus Healthcare has an average rating of "Moderate Buy" and a consensus target price of $11.67.

Sensus Healthcare Trading Up 2.8%

Shares of SRTS traded up $0.13 during midday trading on Thursday, hitting $4.82. 34,728 shares of the company's stock traded hands, compared to its average volume of 207,398. Sensus Healthcare has a 1 year low of $4.01 and a 1 year high of $9.33. The firm's fifty day moving average is $4.61 and its 200-day moving average is $6.04. The stock has a market capitalization of $79.26 million, a price-to-earnings ratio of 12.05 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The firm had revenue of $8.34 million during the quarter, compared to analysts' expectations of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, equities research analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently modified their holdings of the business. IFP Advisors Inc acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $95,000. NewEdge Advisors LLC acquired a new stake in Sensus Healthcare in the 4th quarter worth about $109,000. Arrowstreet Capital Limited Partnership boosted its holdings in Sensus Healthcare by 81.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after buying an additional 67,269 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Sensus Healthcare by 30.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after buying an additional 88,953 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Sensus Healthcare in the 4th quarter worth about $27,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.